$51.42
-2.84-5.23%
Ult. Agg.: Nov 2, 7:35 AM
CRISPR Therapeutics (CRSP) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.18 | $-1.22 | $-1.20 | $-1.30 |
| Actual | $-0.94 | $-1.28 | $-1.37 | $-1.17 |
| Surprise | +20.3% | -4.92% | -14.2% | +10.0% |
| Revenue | ||||
| Estimate | $7.1M | $5.1M | $3.9M | $8.1M |
| Actual | $10.2M | $1.5M | $864000 | $889000 |
| Surprise | +43.0% | -71.2% | -78.0% | -89.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.06 | $-1.17 | $-0.89 | $-0.86 |
| Revenue | ||||
| Consensus | $15.2M | $16.0M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $-0.94 | $-1.18 | 20.3 % |
| Q1 | May 4, 2026 | $-1.28 | $-1.22 | -4.92 % |
| Q4 | Feb 12, 2026 | $-1.37 | $-1.20 | -14.2 % |
| Q3 | Nov 10, 2025 | $-1.17 | $-1.30 | 10.0 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $10.18M | $7.12M | 43.0 % |
| Q1 | May 4, 2026 | $1.46M | $5.06M | -71.2 % |
| Q4 | Feb 12, 2026 | $864.00K | $3.92M | -78.0 % |
| Q3 | Nov 10, 2025 | $889.00K | $8.06M | -89.0 % |